- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Longeveron files $70M mixed securities shelf | 1 | Seeking Alpha | ||
| 20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 211 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
| 14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 189 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen | |
| 03.03. | Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 28.02. | Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update | 307 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more... ► Artikel lesen | |
| 28.02. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.02. | Longeveron Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 18.02. | Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B | 1 | GlobeNewswire (USA) | ||
| 30.01. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | Longeveron to Present at Biotech Showcase 2025 | 3 | GlobeNewswire (USA) | ||
| 13.11.24 | Longeveron reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.24 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.11.24 | A Look Ahead: Longeveron's Earnings Forecast | 5 | Benzinga.com | ||
| 11.11.24 | Longeveron ernennt Devin Blass zum neuen CTO | 2 | Investing.com Deutsch | ||
| 11.11.24 | Longeveron names Devin Blass as new CTO | 1 | Investing.com | ||
| 11.11.24 | Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) | 2 | GlobeNewswire (USA) | ||
| 04.11.24 | Peeling Back The Layers: Exploring Longeveron Through Analyst Insights | 1 | Benzinga.com | ||
| 27.10.24 | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 134 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 10.07.24 | Pre-market Movers: VivoPower, NaaS Technology, Ampco-Pittsburgh, LegalZoom.com, Longeveron | 817 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green VivoPower International PLC (VVPR) is up over 90%... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 102,10 | -0,10 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| CUREVAC | 2,830 | -1,05 % | CureVac-Aktie: Das wird zum Kracher! | News von Trading-Treff.de Eine erneut vernichtende Entwicklung nimmt nun die Aktie von CureVac. Das Papier hat am Donnerstag einen Abschlag in Höhe von -1,6% hinnehmen müssen. Damit ist die Aktie aktuell... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 33,800 | -1,74 % | CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? | ||
| OCUGEN | 0,630 | -2,51 % | Ocugen Aktie: Leichte Erholung nach schwierigem Jahr | Trotz langfristiger Verluste halten Analysten an positiven Bewertungen für Ocugen fest. Die Gentherapie-Pipeline bleibt der zentrale Hoffnungsträger. Die Ocugen-Aktie zeigt heute eine leichte Erholung... ► Artikel lesen | |
| CYTODYN | 0,196 | 0,00 % | CytoDyn Inc.: March 2025 Letter to Shareholders | VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,059 | +14,26 % | SOL Global Investments Corp.: SOL Global Announces Update on C$10 Million Debenture Private Placement from Strategic Investor | Toronto, Ontario--(Newsfile Corp. - March 21, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
| CELLECTIS | 1,416 | +0,71 % | Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal | ||
| ANAVEX LIFE SCIENCES | 8,302 | +0,29 % | Anavex Life Sciences Aktie: Leichter Aufwärtstrend | Anavex-Aktie mit stabiler Performance und optimistischen Analystenprognosen. Biotech-Firma forciert klinische Studien für neurologische Therapien. Die Anavex Life Sciences-Aktie zeigt heute eine stabile... ► Artikel lesen | |
| CERUS | 1,187 | -5,72 % | Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 1,210 | +4,31 % | WINDTREE THERAPEUTICS INC /DE/ - S-1/A, General form for registration of securities | ||
| APTEVO THERAPEUTICS | 0,687 | 0,00 % | Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology... ► Artikel lesen | |
| TRACON PHARMACEUTICALS | 1,410 | 0,00 % | Tracon Pharmaceuticals, Inc. - 15-12G, Securities registration termination | ||
| HARVARD BIOSCIENCE | 0,356 | +4,09 % | Harvard Bioscience, Inc.: Harvard Bioscience Announces CFO Transition | HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer... ► Artikel lesen | |
| ENTERA BIO | 2,020 | +12,10 % | Entera Bio Ltd.: Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates | JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and... ► Artikel lesen | |
| XBRANE BIOPHARMA | 0,007 | -37,61 % | Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB | Today on 14 April 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting. Resolution regarding approval of sale of certain... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,060 (+3,68 %) liegt der Kurs bei 1,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.
